Nasal spray COVID vaccine shows promise in first trial
Nasal Splash COVID Antibody Appears Guarantee in Early Trial
WEDNESDAY, Oct. 11, 2023 (HealthDay News) -- New research points to the potential of a COVID-19 vaccine delivered through the nose.
Phase 1 clinical trials showed that the product, administered intranasally in two doses, resulted in a significant immune response against several COVID variants.
Called CoviLiv, the vaccine was tested as a primary series in healthy adults before developing the mRNA vaccine now approved to treat COVID.
Instead, CoviLiv is a live attenuated vaccine, meaning it is made from a weakened virus. According to developer Codagenix Inc., the virus's genetic material has been recoded to transform it from a disease-causing pathogen into a stable and safe vaccine.
According to the company's press release about the study, participants who received the vaccine during the trial showed a strong immune response. They also demonstrated T cell reactivity that was found to be specific to several viral antigens in addition to the frequently mutating coronavirus spike protein.
The idea is to create an immune response against the entire virus rather than against the frequently mutated Spike protein. Researchers say this has the potential to provide broader protection against variants.
None of the current COVID vaccines are live attenuated or administered intranasally.
The results are expected to be presented Wednesday at IDWeek 2023, the joint annual meeting of several organizations, including the Infectious Diseases Society of America, in Boston.
“The study results provide insight into the next generation of COVID-19 vaccines,” said study lead author Johanna Kaufmann, executive vice president of oncology and immunology at Codagenix Inc. could provide differentiated protection to more people.”
“Intranasal vaccine delivery and easier storage could increase vaccine access in underserved areas around the world,” she said in a press release.
CoviLiv does not require cold chain storage, which will facilitate storage in areas without sufficient refrigeration. Having an alternative to the COVID vaccine could also increase vaccination rates in areas with lower vaccination rates, according to the study.
Results presented at medical meetings are considered preliminary until published in a peer-reviewed journal.

Comments
Post a Comment